Trial
NCT03689829
A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Lakefront Biotherapeutics NV
Collaborators
—
Condition
Healthy
Intervention
MOR106
Why stopped
MOR106 clinical development in atopic dermatitis was stopped for futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-03-18